CD8 (Cluster of Differentiation 8) is a transmembrane glycoprotein that functions as a co-receptor for T-cell receptor (TCR) and therefore binds to MHC molecules. There are existing two isoforms (alpha and beta). This antibody is a T-cell marker that detects cytotoxic/suppressor cells of blood lymphocytes, NK cells and most thymocytes. It is helpful in differentiation of reactive and neoplastic T-cells.

[1] Chiba T, Ohtani H, Mizoi T et al. (2004): Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer. 91(9):1711-7.
[2] Sato E, Olson SH, Ahn J et al. (2005): Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 102(51):18538-43.
[3] Gupta N, Kumar S, Singh G and Basu A (2015): Adult T cell large granular lymphocytic leukemia. Med J Armed Forces India. 71(1):272-5.
[4] Bhaker P, Das A, Rajwanshi A et al. (2015): Precursor T-lymphoblastic lymphoma: Speedy diagnosis in FNA and effusion cytology by morphology, immunochemistry, and flow cytometry. Cancer Cytopathol. 123(9):557-65.